PURPOSE: To determine long-term outcomes in a clinical trial evaluating the role of @entity3907 type and schedule in operable @entity0 and evaluate the impact of @entity28 and black race on outcome. @entity1 AND METHODS: A total of 4,954 eligible @entity1 with @entity0 treated with four cycles of @entity632 plus @entity786 were randomly assigned to receive @entity1311 or @entity1205 every 3 weeks for four doses or weekly for 12 doses using a 2 * 2 factorial design. The primary end point was disease-free survival (DFS). Results are expressed as hazard ratios (HRs) from Cox proportional hazards models. All P values are two sided. RESULTS: When compared with the standard every-3-week @entity1311 arm, after a median follow-up of 12.1 years, DFS significantly improved and @entity1349 ( @entity1349 ) marginally improved only for the weekly @entity1311 (HR, 0.84; P = .011 and HR, 0.87; P = .09, respectively) and every-3-week docetaxel arms (HR, 0.79; P = .001 and HR, 0.86; P = .054, respectively). Weekly @entity1311 improved DFS and @entity1349 (HR, 0.69; P = .010 and HR, 0.69; P = .019, respectively) in triple-negative @entity0 . For hormone receptor-positive, @entity1 @entity1722 -nonoverexpressing disease, no experimental arm improved @entity1349 , and black race and @entity28 were associated with increased risk of @entity0 recurrence and @entity204 . CONCLUSION: Improved outcomes initially observed for weekly @entity1311 were qualitatively similar but quantitatively less pronounced with longer follow-up, although exploratory analysis suggested substantial benefit in triple-negative disease. Further research is required to understand why @entity28 and race influence clinical outcome in hormone receptor-positive disease.

Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of XXXX and Schedule in Operable @entity0 .

@entity1 :: ('9606', 'Species') :: ['women', 'human', 'PATIENTS'] @entity632 :: ('MESH:D004317', 'Chemical') :: ['doxorubicin'] @entity0 :: ('MESH:D001943', 'Disease') :: ['stage II to III breast cancer', 'breast cancer'] @entity28 :: ('MESH:D009765', 'Disease') :: ['obesity'] @entity1722 :: ('2064', 'Gene') :: ['epidermal growth factor receptor 2'] @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity3907 :: (MESH:C080625,Chemical) :: ['Taxane']
